Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

David A Muller; Frances E Pearson; Germain J P Fernando; Christiana Agyei-Yeboah; Nick S Owens; Simon Robert Corrie; Michael L Crichton; Jonathan C J Wei; William Clyde Weldon; M Steven Oberste; Paul R Young; Mark Anthony Fernance Kendall

doi:10.1038/srep22094

Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

David A Muller, Frances E Pearson, Germain J P Fernando, Christiana Agyei-Yeboah, Nick S Owens, Simon Robert Corrie, Michael L Crichton, Jonathan C J Wei, William Clyde Weldon, M Steven Oberste, Paul R Young, Mark Anthony Fernance Kendall

Research output: Contribution to journal › Article › Research › peer-review

38 Citations (Scopus)

Abstract

Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns.

Original language	English
Article number	22094
Pages (from-to)	1 - 7
Number of pages	7
Journal	Scientific Reports
Volume	6
DOIs	https://doi.org/10.1038/srep22094
Publication status	Published - 25 Feb 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep22094

3624112-oaFinal published version, 660 KB

Cite this

Muller, D. A., Pearson, F. E., Fernando, G. J. P., Agyei-Yeboah, C., Owens, N. S., Corrie, S. R., Crichton, M. L., Wei, J. C. J., Weldon, W. C., Oberste, M. S., Young, P. R., & Kendall, M. A. F. (2016). Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Scientific Reports, 6, 1 - 7. [22094]. https://doi.org/10.1038/srep22094

@article{8ec7cf5ce02848928ebbf8eea1e1450e,

title = "Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses",

abstract = "Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns.",

author = "Muller, {David A} and Pearson, {Frances E} and Fernando, {Germain J P} and Christiana Agyei-Yeboah and Owens, {Nick S} and Corrie, {Simon Robert} and Crichton, {Michael L} and Wei, {Jonathan C J} and Weldon, {William Clyde} and Oberste, {M Steven} and Young, {Paul R} and Kendall, {Mark Anthony Fernance}",

year = "2016",

month = feb,

day = "25",

doi = "10.1038/srep22094",

language = "English",

volume = "6",

pages = "1 -- 7",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

Muller, DA, Pearson, FE, Fernando, GJP, Agyei-Yeboah, C, Owens, NS, Corrie, SR, Crichton, ML, Wei, JCJ, Weldon, WC, Oberste, MS, Young, PR & Kendall, MAF 2016, 'Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses', Scientific Reports, vol. 6, 22094, pp. 1 - 7. https://doi.org/10.1038/srep22094

TY - JOUR

T1 - Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

AU - Muller, David A

AU - Pearson, Frances E

AU - Fernando, Germain J P

AU - Agyei-Yeboah, Christiana

AU - Owens, Nick S

AU - Corrie, Simon Robert

AU - Crichton, Michael L

AU - Wei, Jonathan C J

AU - Weldon, William Clyde

AU - Oberste, M Steven

AU - Young, Paul R

AU - Kendall, Mark Anthony Fernance

PY - 2016/2/25

Y1 - 2016/2/25

N2 - Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns.

AB - Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns.

U2 - 10.1038/srep22094

DO - 10.1038/srep22094

M3 - Article

VL - 6

SP - 1

EP - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 22094

ER -